Hyperacute transplant rejection vs Acute and chronic transplant rejection
How to tell Hyperacute transplant rejection and Acute and chronic transplant rejection apart when a board question makes them look alike.
Hyperacute is preformed antibody minutes-hours; acute is T-cell/antibody days-months; chronic is intimal fibrosis months-years.
Side by side
Hyperacute rejection occurs minutes to hours after transplant from preformed recipient anti-donor antibodies causing complement activation, thrombosis, and ischemic graft necrosis.
Acute rejection occurs days to months from T cells or newly formed antibodies; chronic rejection occurs months to years with progressive vascular intimal fibrosis and graft dysfunction.
Preexisting anti-ABO or anti-HLA antibodies bind graft endothelium immediately and trigger complement-mediated endothelial injury.
Acute cellular or humoral immunity attacks graft after activation; chronic immune injury and repair cause vasculopathy, fibrosis, and gradual loss.
Immediate graft cyanosis, thrombosis, neutrophils, fibrinoid necrosis, and positive crossmatch support hyperacute rejection.
Interstitial lymphocytes/tubulitis or antibody-mediated vasculitis supports acute; intimal thickening and fibrosis support chronic.
The trap
All three reduce graft function but the timing and mechanism differ, which changes management. HYPERACUTE rejection happens within minutes to hours of transplantation: the recipient has PRE-FORMED antibodies against donor antigens (ABO blood group incompatibility, prior pregnancy or transfusion, prior transplant), causing immediate antibody-mediated complement activation, vascular thrombosis, and graft necrosis; treatment is removal of the graft; prevent by ABO matching and crossmatching. ACUTE rejection happens days to months post-transplant: dominant mechanism is T-cell mediated (cellular rejection: lymphocyte infiltration on biopsy) but antibody-mediated acute rejection can also occur (vascular C4d deposition); presents as graft dysfunction or fever; treat with pulse corticosteroids plus immunosuppression intensification (anti-thymocyte globulin for steroid-resistant cellular rejection; plasmapheresis plus IVIG plus rituximab for antibody-mediated rejection). CHRONIC rejection happens months to years post-transplant: progressive arteriopathy with intimal smooth muscle proliferation, interstitial fibrosis, and parenchymal atrophy; presents as gradual graft dysfunction (creatinine creep in renal transplant, bronchiolitis obliterans in lung transplant, cardiac allograft vasculopathy in heart transplant); poorly responsive to therapy, often requires re-transplantation.
The repair move
For transplant rejection, start with timing, then identify antibody, T-cell, or chronic vascular fibrosis.
Try a free question
CoreA patient receives a kidney transplant and, within 30 minutes of the vascular anastomosis being completed, the kidney becomes cyanotic and mottled, urine production stops, and the surgeon removes the graft. Crossmatch in retrospect shows preformed recipient anti-donor HLA antibodies. Pathology shows widespread arteriolar thrombosis and fibrinoid necrosis. Which type of rejection is this?
Show answer and explanation
Answer: A. Hyperacute rejection. Hyperacute rejection occurs minutes to hours after transplantation from PREFORMED recipient antibodies against donor antigens (ABO incompatibility, prior pregnancy, prior transfusion, prior transplant). Antibody binds graft endothelium, activates complement, and produces immediate thrombosis and fibrinoid necrosis. The graft must be removed. Prevent by ABO matching and crossmatching.
Why the other choices are tempting
- B. Acute cellular rejection occurs days to months later with lymphocyte infiltration and tubulitis.
- C. Acute antibody-mediated rejection occurs days to weeks with C4d deposition on biopsy and de novo antibody.
- D. Chronic rejection occurs months to years with intimal fibrosis and gradual graft dysfunction.
- E. Drug-induced nephrotoxicity (calcineurin inhibitor toxicity) is gradual and not immediate vascular thrombosis.
Flashcards
Tap a card to flip it.
What clue supports Hyperacute transplant rejection?
Choose Hyperacute transplant rejection when the stem gives this pattern: Hyperacute rejection occurs minutes to hours after transplant from preformed recipient anti-donor antibodies causing complement activation, thrombosis, and ischemic graft necrosis.
What clue supports Acute and chronic transplant rejection?
Choose Acute and chronic transplant rejection when the stem gives this contrasting pattern: Acute rejection occurs days to months from T cells or newly formed antibodies; chronic rejection occurs months to years with progressive vascular intimal fibrosis and graft dysfunction.
Quick answers
What is the fastest way to tell Hyperacute transplant rejection from Acute and chronic transplant rejection?
Hyperacute is preformed antibody minutes-hours; acute is T-cell/antibody days-months; chronic is intimal fibrosis months-years.
What is the key clue for Hyperacute transplant rejection?
Hyperacute rejection occurs minutes to hours after transplant from preformed recipient anti-donor antibodies causing complement activation, thrombosis, and ischemic graft necrosis.
What is the key clue for Acute and chronic transplant rejection?
Acute rejection occurs days to months from T cells or newly formed antibodies; chronic rejection occurs months to years with progressive vascular intimal fibrosis and graft dysfunction.
What is the common trap with Hyperacute transplant rejection vs Acute and chronic transplant rejection?
All three reduce graft function but the timing and mechanism differ, which changes management. HYPERACUTE rejection happens within minutes to hours of transplantation: the recipient has PRE-FORMED antibodies against donor antigens (ABO blood group incompatibility, prior pregnancy or transfusion, prior transplant), causing immediate antibody-mediated complement activation, vascular thrombosis, and graft necrosis; treatment is removal of the graft; prevent by ABO matching and crossmatching. ACUTE rejection happens days to months post-transplant: dominant mechanism is T-cell mediated (cellular rejection: lymphocyte infiltration on biopsy) but antibody-mediated acute rejection can also occur (vascular C4d deposition); presents as graft dysfunction or fever; treat with pulse corticosteroids plus immunosuppression intensification (anti-thymocyte globulin for steroid-resistant cellular rejection; plasmapheresis plus IVIG plus rituximab for antibody-mediated rejection). CHRONIC rejection happens months to years post-transplant: progressive arteriopathy with intimal smooth muscle proliferation, interstitial fibrosis, and parenchymal atrophy; presents as gradual graft dysfunction (creatinine creep in renal transplant, bronchiolitis obliterans in lung transplant, cardiac allograft vasculopathy in heart transplant); poorly responsive to therapy, often requires re-transplantation.